Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C16H12Cl2N2O2 |
| Molecular Weight | 335.185 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C2=C(C=C(Cl)C=C2)C(=NC(O)C1=O)C3=C(Cl)C=CC=C3
InChI
InChIKey=FJIKWRGCXUCUIG-UHFFFAOYSA-N
InChI=1S/C16H12Cl2N2O2/c1-20-13-7-6-9(17)8-11(13)14(19-15(21)16(20)22)10-4-2-3-5-12(10)18/h2-8,15,21H,1H3
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/1687574
https://www.ncbi.nlm.nih.gov/pubmed/6124982
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/1687574
https://www.ncbi.nlm.nih.gov/pubmed/6124982
Lormetazepam (or methyl-lorazepam), possesses hypnotic, anxiolytic, sedative and skeletal muscle relaxant properties. Lormetazepam is not approved for sale in the United States or Canada, though it is licensed in the Netherlands as 1 and 2 mg tablets, under the brand names Loramet and Noctamid and as generic, available from several different manufacturers. Lormetazepam is a short-acting benzodiazepine and is sometimes used in patients who have difficulty in maintaining sleep or falling asleep. Lormetazepam binds to the benzodiazepine receptor which in turn enhances the effect of the GABAA receptor producing its therapeutic effects as well as adverse effects. Lormetazepam appears to be more selective in the type of benzodiazepine receptor it binds to showing a higher affinity for the omega 1 receptor which is responsible for sedation. Changes in electroencephalography can therefore be used to measure the sedative sleep promoting properties of lormetazepam.
CNS Activity
Sources: https://web.archive.org/web/20131021001657/http://www.cinfainternational.com/producto/lormetazepam/
Curator's Comment: Lormetazepam acts through the central nervous system
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Simultaneous determination of fifteen low-dosed benzodiazepines in human urine by solid-phase extraction and gas chromatography-mass spectrometry. | 2001 Dec 25 |
|
| Adsorption of xenobiotics to plastic tubing incorporated into dynamic in vitro systems used in pharmacological research--limits and progress. | 2001 Jul |
|
| Fast withdrawal from benzodiazepines in geriatric inpatients: a randomised double-blind, placebo-controlled trial. | 2002 Jan |
|
| Immobilized halogenophenylcarbamate derivatives of cellulose as novel stationary phases for enantioselective drug analysis. | 2002 Jan 15 |
|
| Lormetazepam effects on daytime vigilance, psychomotor performance and simulated driving in young adult healthy volunteers. | 2002 Jul |
|
| Determination of lormetazepam and its main metabolite in serum using micellar electrokinetic capillary chromatography with direct injection and ultraviolet absorbance detection. | 2002 Jun 25 |
|
| Effects of short-acting hypnotics on sleep latency in rats placed on grid suspended over water. | 2003 Jan 24 |
|
| Effects on postural oscillation and memory functions of a single dose of zolpidem 5 mg, zopiclone 3.75 mg and lormetazepam 1 mg in elderly healthy subjects. A randomized, cross-over, double-blind study versus placebo. | 2003 Jul |
|
| The use of hypnosedative drugs in a university hospital setting. | 2003 Jul-Aug |
|
| Screening, library-assisted identification and validated quantification of 23 benzodiazepines, flumazenil, zaleplone, zolpidem and zopiclone in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. | 2004 Aug |
|
| Lormetazepam in depressive insomnia: new evidence of phase-response effects of benzodiazepines. | 2004 Sep |
|
| Quantification of lorazepam and lormetazepam in human breast milk using GC-MS in the negative chemical ionization mode. | 2007 May |
|
| Evaluation of anxiolytic-like effects of some short-acting benzodiazepine hypnotics in mice. | 2008 Jul |
|
| A validated method for simultaneous screening and quantification of twenty-three benzodiazepines and metabolites plus zopiclone and zaleplone in whole blood by liquid-liquid extraction and ultra-performance liquid chromatography- tandem mass spectrometry. | 2010 Jul-Aug |
|
| Experimental design for optimization of microwave-assisted extraction of benzodiazepines in human plasma. | 2010 May |
|
| Analysis of six benzodiazepines in vitreous humor by high-performance liquid chromatography-photodiode-array detection. | 2010 Nov |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1012
Created by
admin on Fri Dec 15 15:26:14 UTC 2023 , Edited by admin on Fri Dec 15 15:26:14 UTC 2023
|
||
|
WHO-ATC |
N05CD06
Created by
admin on Fri Dec 15 15:26:14 UTC 2023 , Edited by admin on Fri Dec 15 15:26:14 UTC 2023
|
||
|
DEA NO. |
2774
Created by
admin on Fri Dec 15 15:26:14 UTC 2023 , Edited by admin on Fri Dec 15 15:26:14 UTC 2023
|
||
|
WHO-VATC |
QN05CD06
Created by
admin on Fri Dec 15 15:26:14 UTC 2023 , Edited by admin on Fri Dec 15 15:26:14 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL22097
Created by
admin on Fri Dec 15 15:26:14 UTC 2023 , Edited by admin on Fri Dec 15 15:26:14 UTC 2023
|
PRIMARY | |||
|
C023842
Created by
admin on Fri Dec 15 15:26:14 UTC 2023 , Edited by admin on Fri Dec 15 15:26:14 UTC 2023
|
PRIMARY | |||
|
m6909
Created by
admin on Fri Dec 15 15:26:14 UTC 2023 , Edited by admin on Fri Dec 15 15:26:14 UTC 2023
|
PRIMARY | Merck Index | ||
|
DTXSID40862442
Created by
admin on Fri Dec 15 15:26:14 UTC 2023 , Edited by admin on Fri Dec 15 15:26:14 UTC 2023
|
PRIMARY | |||
|
212-700-5
Created by
admin on Fri Dec 15 15:26:14 UTC 2023 , Edited by admin on Fri Dec 15 15:26:14 UTC 2023
|
PRIMARY | |||
|
848-75-9
Created by
admin on Fri Dec 15 15:26:14 UTC 2023 , Edited by admin on Fri Dec 15 15:26:14 UTC 2023
|
PRIMARY | |||
|
52993
Created by
admin on Fri Dec 15 15:26:14 UTC 2023 , Edited by admin on Fri Dec 15 15:26:14 UTC 2023
|
PRIMARY | |||
|
LORMETAZEPAM
Created by
admin on Fri Dec 15 15:26:14 UTC 2023 , Edited by admin on Fri Dec 15 15:26:14 UTC 2023
|
PRIMARY | |||
|
13314
Created by
admin on Fri Dec 15 15:26:14 UTC 2023 , Edited by admin on Fri Dec 15 15:26:14 UTC 2023
|
PRIMARY | |||
|
GU56C842ZA
Created by
admin on Fri Dec 15 15:26:14 UTC 2023 , Edited by admin on Fri Dec 15 15:26:14 UTC 2023
|
PRIMARY | |||
|
4339
Created by
admin on Fri Dec 15 15:26:14 UTC 2023 , Edited by admin on Fri Dec 15 15:26:14 UTC 2023
|
PRIMARY | |||
|
SUB08588MIG
Created by
admin on Fri Dec 15 15:26:14 UTC 2023 , Edited by admin on Fri Dec 15 15:26:14 UTC 2023
|
PRIMARY | |||
|
DB13872
Created by
admin on Fri Dec 15 15:26:14 UTC 2023 , Edited by admin on Fri Dec 15 15:26:14 UTC 2023
|
PRIMARY | |||
|
Lormetazepam
Created by
admin on Fri Dec 15 15:26:14 UTC 2023 , Edited by admin on Fri Dec 15 15:26:14 UTC 2023
|
PRIMARY | |||
|
28894
Created by
admin on Fri Dec 15 15:26:14 UTC 2023 , Edited by admin on Fri Dec 15 15:26:14 UTC 2023
|
PRIMARY | RxNorm | ||
|
100000091985
Created by
admin on Fri Dec 15 15:26:14 UTC 2023 , Edited by admin on Fri Dec 15 15:26:14 UTC 2023
|
PRIMARY | |||
|
C87673
Created by
admin on Fri Dec 15 15:26:14 UTC 2023 , Edited by admin on Fri Dec 15 15:26:14 UTC 2023
|
PRIMARY | |||
|
1608
Created by
admin on Fri Dec 15 15:26:14 UTC 2023 , Edited by admin on Fri Dec 15 15:26:14 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (METABOLITE)
